Innate Pharma Achieves Phase 1 Milestone for IPH4502 ADC with Linker Stability Signal
Innate Pharma's IPH4502 Phase 1 data show linker stability signal and 33% ORR at MTD; dose optimization begins H1 2027.


Innate Pharma's Phase 1 data for IPH4502, presented at ENA 2026, carry a manufacturing signal that QA and process development teams should note: low circulating free-exatecan levels in 76 heavily pretreated patients point to linker stability performing as designed under in vivo conditions, a finding that directly informs GMP release specifications and payload containment strategies for this class of highly potent ADC.
The dose-escalation study enrolled patients across six dose levels from 0.6 mg/kg to 3.6 mg/kg administered Q3W, establishing a maximum tolerated dose (MTD) of 3.6 mg/kg. Stomatitis was the only dose-limiting toxicity reported; no febrile neutropenia, no hematologic dose-limiting toxicities, and no peripheral neuropathy signal emerged. Grade 3 or higher treatment-emergent adverse events occurred in 43.4% of patients, with dose reductions in 7.9% and discontinuations in 5.3%. The hematologic tolerability profile, atypical for exatecan-based payloads, is consistent with the linker holding integrity in systemic circulation.
For ADC manufacturers and QC leads, the low free-payload exposure data reinforce the criticality of linker characterization assays within the 21 CFR Part 211 quality framework. Premature payload release remains one of the primary failure modes in ADC production, and in vivo stability data of this kind feed directly into drug substance specifications, comparability protocols, and process validation acceptance criteria. The exatecan payload class, increasingly prevalent across oncology pipelines, demands containment controls and dedicated highly potent API (HPAPI) manufacturing suites with validated occupational exposure band assessments.
On the clinical side, antitumor activity was observed across tumor types and Nectin-4 expression levels. An objective response rate of 33% (2/6) was recorded at the MTD in non-urothelial tumors. Among the 19 urothelial cancer patients, all of whom had prior enfortumab vedotin exposure, none were enrolled at the 3.6 mg/kg MTD level, leaving the post-EV urothelial cohort at higher doses uncharacterized. Innate has indicated dose optimization will begin with first patient enrollment planned for H1 2027, targeting upper dose levels in post-EV urothelial cancer to define a recommended Phase 2 dose and schedule.
The data cutoff was August 17, 2026, and results were presented as a poster at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
The H1 2027 dose-optimization cohort will be the next measurable checkpoint for both the clinical program and the manufacturing scale decisions that follow a recommended Phase 2 dose determination.
Source: Innate Pharma SA via press release, November 17, 2026. A KOL webcast was hosted same-day at 11:00 a.m. ET / 4:00 p.m. GMT.

Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from Pharma News
All stories →
EktaH Advances NKS-3 Obesity Drug into Phase IIa After Securing €2.4 Million Funding

Merck Discontinues BELLWAVE-011 Phase 3 Trial for Nemtabrutinib

Discussion